Association of glass syndrome with Chiari malformation type I: a rare case report from the Brazilian public healthcare system
Abstract
Case Presentation: A 38-year-old woman was diagnosed in early childhood with epilepsy, severe intellectual disability, and neurodevelopmental delay. She also presented with overweight, osteopenia, facial dysmorphism, orthodontic abnormalities, and expressive aphasia, while maintaining appropriate sociability and social behavior. She had a previous history of traumatic brain injury and physical assault, which were initially considered the cause of her epilepsy. Her seizures were characterized as focal seizures with impaired awareness, presenting with sudden behavioral arrest, dysautonomia, cutaneous pallor, and an emotional aura of intense fear lasting a few minutes. Since symptom onset, she had been followed by neurological and multidisciplinary teams through the Brazilian Unified Health System (SUS) and treated with antiseizure medications, achieving satisfactory seizure control without further diagnostic investigation. Neuroimaging was performed only at 35 years of age, revealing platybasia, Chiari malformation type I (CM1), high cervical segmental syringomyelia, and left hippocampal volume loss suggestive of mesial temporal sclerosis. The combination of clinical and neuroimaging findings raised the suspicion of an underlying genetic syndrome. Whole-exome sequencing, performed through the SUS, identified a heterozygous likely pathogenic variant in the SATB2 gene, confirming the diagnosis of SATB2-associated syndrome, also known as Glass syndrome (GS). The molecular diagnosis was consistent with the clinical phenotype, including multiple manifestations of GS. Discussion: CM1 is characterized by herniation of the cerebellar tonsils through the foramen magnum, potentially obstructing cerebrospinal fluid flow and predisposing to syringomyelia, affecting approximately 0.1% of the global population. In contrast, GS is a rare disorder, with fewer than 700 cases reported in the medical literature, characterized by neurodevelopmental impairment and other clinical manifestations. It is a rare autosomal dominant neurodevelopmental disorder caused by pathogenic variants or haploinsufficiency of the SATB2 gene, most commonly resulting from microdeletions involving chromosome region 2q33.1. Expression of SATB2 in the pharyngeal arches explains the characteristic craniofacial abnormalities of GS, including micrognathia, cleft palate, high-arched palate, and dental anomalies. Osteopenia has been reported in approximately 26% of patients with GS, whereas epilepsy occurs in about 20% of cases. Although structural brain abnormalities are common in GS, the association with CM1 has not previously been reported. Final Comments: Recognizing the broad phenotypic spectrum of GS and the challenges of its diagnosis, particularly in public healthcare systems such as the SUS, makes this case particularly noteworthy. The previously unreported association between GS and CM1 highlights the clinical relevance of this report. Further studies are warranted to clarify this association and improve the understanding of GS.